YBX1 and hepatocellular carcinoma: recently found that increased expression of circRNA-SORE maintained sorafenib resistance in HCC mainly through two mechanisms: (i) sponging miR-103a-2-5p/miR-660-3p and activating the Wnt/β-catenin pathway; in particular, N6-methyladenosine-modified circRNA-SORE increased circRNA-SORE expression by increasing RNA stability (134); (ii) circRNA-SORE bound and stabilized YBX1 by preventing PRP19-mediated degradation of YBX1; in addition, circRNA-SORE (which was transported by exosomes) could transmit sorafenib resistance among HCC cells (135).